Results 151 to 160 of about 25,328 (173)

Durvalumab

Reactions Weekly
  +14 more sources

Durvalumab

Reactions Weekly, 2023
  +9 more sources

Durvalumab

Reactions Weekly, 2019
  +7 more sources

Durvalumab With or Without Tremelimumab Versus the EXTREME Regimen as First-Line Treatment for Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: KESTREL, a Randomized, Open-Label, Phase III Study

Annals of Oncology, 2023
J Fayette, M-J Ahn, A Psyrri
exaly  

Neoadjuvant Durvalumab Improves Survival in Early Triple-Negative Breast Cancer Independent of Pathological Complete Response☆

Annals of Oncology, 2022
J-U Blohmer, P A Fasching, P A Fasching
exaly  

Phase II Study of Ceralasertib (AZD6738) in Combination With Durvalumab in Patients With Advanced/Metastatic Melanoma Who Have Failed Prior Anti-PD-1 Therapy

Annals of Oncology, 2022
S T Kim, W-Y Park, M An
exaly  

Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy

Journal of Thoracic Oncology, 2021
Ravi Salgia, Summer S. Han
exaly  

ARCTIC: Durvalumab With or Without Tremelimumab as Third-Line or Later Treatment of Metastatic Non-Small-Cell Lung Cancer☆

Annals of Oncology, 2020
Dariusz Kowalski, S L Geater, M McCleod
exaly  

Durvalumab, With or Without Tremelimumab, Plus Platinum-Etoposide in First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer: 3-Year Overall Survival Update From CASPIAN☆

ESMO Open, 2022
Luis Paz-Ares, J H Ji, J W Goldman
exaly  

Durvalumab With or Without Tremelimumab in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: EAGLE, a Randomized, Open-Label Phase III Study

Annals of Oncology, 2020
Makoto Tahara, Ricard Mesia
exaly